Discover a study where patients reported symptom relief as early as one week after starting treatment, with continued ...

Their ages ranged from 17-26 years (mean age, 20.1 years). All patients had axillary hyperhidrosis of 1-6 year duration, with an average of 2.9 years. Approximately 125 units of botulinum-A toxin ...

Hyperhidrosis is a term used to describe excessive ... traditional surgery to remove subcutaneous tissues containing axillary sweat glands or a form of liposuction (called suction curettage ...

The Japan axillary hyperhidrosis treatment market is experiencing significant growth, with projections indicating a rise from USD 66.9 million in 2025 to USD 134.1 million by 2035, reflecting a CAGR ...

The Canada axillary hyperhidrosis market is poised for significant expansion, with market value expected to grow from USD 65.4 million in 2025 to USD 120.5 million by 2035, reflecting a 6.3% CAGR. The ...

This Phase 2a study will explore DMT410, which combines a single application of XYNGARI™ followed by a topical application of DAXXIFY® for the treatment of axillary hyperhidrosis. Beyond ...

Dr Howie McKibbon, CEO of Botanix Pharmaceuticals (ASX:BOT), discusses the FDA approval and market success of Sofdra, the first new chemical entity approved for primary axillary hyperhidrosis.

The use of intradermal injections of botulinum-A toxin in the treatment of axillary hyperhidrosis was attempted and seems to be an effective and safe mode of therapy with virtually no side effects ...